What a list that is. And this is just the Navy.

While drug pricing is outside of the FDA's jurisdiction and the most robust solutions likely involve HHS and CMS, this is something this committee needs to address this Congress.

If these nations see the United States or the administration, the current administration, being lackadaisical about Russian attacks...

Do you share her view that a budget cut of that magnitude to the NIH would be devastating to medical innovation?

We have to stand true.

I'd like to keep it that way, and I'm hopeful we can move beyond the failed Trumpcare proposal and work together to build on the progress we have made in our healthcare system.

Partnership implies a shared goal, a shared set of values, and the United States and the European Union do have a shared goal of trying to confine Russian aggression.

The astronomical cost of prescription drugs is a financial hardship for so many patients and families and communities, and we need to face up to the tough questions.

Let's be clear. Those tweaks alone will not solve the problem. More work is needed outside the FDA context and outside this committee's jurisdiction to address the root cause of high prices.

Patients and families in my home State of Washington and nationwide deserve to know the devices used in their care are safe and effective, and I'm going to continue fighting for this until we get meaningful safeguards in place so we can…

I think 25 million to 30 million Americans, in total, are affected by rare diseases.

I would like to ask the other witnesses--Ms. Haycombe was asked about the potential effects of a $6 billion cut in NIH to medical innovation.

If we do not send the message that this system is meant to stop people from buying firearms who are prohibited by law from buying firearms, what is the point of this system?

One insurance commissioner told me that if we did not act by April of this year, there would not be insurance sold in his State next year, which is 2018.

Madam Speaker, I rise today in strong opposition to H.R. 1431, the EPA Science Advisory Board Reform Act. Madam Speaker, H.R. 1431 is a blatant attempt to cripple the important mission of the EPA by stacking the EPA Science Advisory Board…

Mr. Speaker, I have several objections to the legislation being considered today. As with the Secret Science Reform Act, the bill would seriously undercut the Environmental Protection Agency's ability to use science to inform their work…

Mr. Speaker, I thank my distinguished friend from Massachusetts, and I also thank his able staff for the incredible work they are doing. Mr. Speaker, I want to talk about the bill before us, the EPA Science Advisory Board, but also I want…

It cleared out an obstacle that was an obstacle for a lot of the other nations.